Panel Narrowly Recommends Medtronic Spine Treatment After Tough Scrutiny
This article was originally published in The Gray Sheet
Executive Summary
An FDA advisory panel cast a mixed vote on July 27 in support of Medtronic's Amplify rhBMP-2 Matrix spinal treatment, reflecting disagreement about safety and the reliability of some clinical data
You may also be interested in...
Medtronic’s Amplify Spine Product Not Approvable, FDA Says
Medtronic received a non-approvable letter from FDA for its Amplify rhBMP-2 Matrix spinal treatment, the company disclosed in a March 9 regulatory filing.
Medtronic’s Amplify Spine Product Not Approvable, FDA Says
Medtronic received a non-approvable letter from FDA for its Amplify rhBMP-2 Matrix spinal treatment, the company disclosed in a March 9 regulatory filing.
Medicare Panel Gives Wish List For Bone Morphogenetic Protein Research
Cross-industry cooperation may be needed to develop more effective bone morphogenetic proteins to promote bone growth and fusion, according to a Medicare advisory panel